<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695769</url>
  </required_header>
  <id_info>
    <org_study_id>HelwanU 76-2020</org_study_id>
    <nct_id>NCT04695769</nct_id>
  </id_info>
  <brief_title>Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders</brief_title>
  <official_title>The Role of Combined Ribavirin and Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment of Chronic Hepatitis C Non-responders; A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helwan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helwan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the role of ribavirin as an adjuvant to&#xD;
      sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with&#xD;
      previous treatment failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2020</start_date>
  <completion_date type="Anticipated">November 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of sustained virological response (SVR)</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Percentage of patients with Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) SVR12 is defined as HCV RNA &lt; the lower limit of quantitation 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Tolerability assessment by reporting of treatment related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A: SOF/VEL/VOX with RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: &lt; or &gt; 60 kg).&#xD;
Another name: Vosevi, RBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: SOF/VEL/VOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).&#xD;
Another name: Vosevi</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin</intervention_name>
    <description>Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.</description>
    <arm_group_label>Group A: SOF/VEL/VOX with RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]</intervention_name>
    <description>Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.</description>
    <arm_group_label>Group B: SOF/VEL/VOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (≥ 18 years) patients with chronic hepatitis C and detectable HCV RNA by&#xD;
             Polymerase Chain Reaction (PCR) after completion of previous direct-acting antiviral&#xD;
             regimen, and eligible for antiviral treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with decompensated cirrhosis (Child-Pugh score B and C).&#xD;
&#xD;
          -  Patients with platelet count less than 50000/ mm³.&#xD;
&#xD;
          -  Patients with HCC or extrahepatic malignancy.&#xD;
&#xD;
          -  Pregnancy or inability to use an effective contraceptive method.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohammed Emadeldeen, Specialist</last_name>
    <phone>00201226181004</phone>
    <email>mo_emad@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed El Kassas, MD</last_name>
    <phone>00201114455552</phone>
    <email>m_elkassas@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine Helwan University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Emadeldeen, MSc</last_name>
      <phone>00201226181004</phone>
      <email>mo_emad@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 3, 2021</last_update_submitted>
  <last_update_submitted_qc>January 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helwan University</investigator_affiliation>
    <investigator_full_name>Mohammed Emadeldeen</investigator_full_name>
    <investigator_title>Hepato-gastroenterology specialist</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Relapse</keyword>
  <keyword>treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

